Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

230 FLUORIDES
Edema
(1995): Saada V+, Ann Dermatol Venereol 122(8), 512 (HF)
Erythema
(2002): Fujimoto K+, J Nippon Med Sch 69(2), 180 (HF)
(1995): Saada V+, Ann Dermatol Venereol 122(8), 512 (HF)
Folliculitis
(1982): Andersen KE+, Contact Dermatitis 8(3), 173 (Triphenyl
tin fluoride in paint)
Inflammation
(2002): Lund K+, Inhal Toxicol 14(2), 119 (HF)
Necrosis
(1999): Sjostrom S+, J Clin Periodontol 26(4), 257 (SF gel)
(1995): Saada V+, Ann Dermatol Venereol 122(8), 512 (HF)
Papulo-nodular lesions
Perioral dermatitis
(1992): Ferlito TA, J Clin Orthod 26(1), 43
Pruritus
Pustules
(1985): Dooms-Goossens A+, Contact Dermatitis 12(1), 42
(NaF)
Side effects (sic)
(1987): Rubenstein LK+, ASDC J Dent Child 54(4), 245 (topical F)
Urticaria
(1993): Camarasa JG+, Contact Dermatitis 28(5), 294 (NaF)
Vesiculation
(2002): Fujimoto K+, J Nippon Med Sch 69(2), 180 (HF)
Mucosal
Aphthous stomatitis
Gingival lesions
(2000): Banks PA+, Eur J Orthod 22(4), 401 (50% [SF])
Mucosal irritation
Oral ulceration
Stomatitis
(1997): Ganter G+, Contact Dermatitis 37(5), 248
(1993): Isaksson M+, Scand J Dent Res 101(1), 49 (Duraphat)
Xerostomia
(1985): Grad H+, J Can Dent Assoc 51(4), 296
Eyes
Cataract
(1985): Thienpont P+, Bull Soc Ophtalmol Fr 85(2), 253 (SF6)
(1983): Werry H+, Klin Monatsbl Augenheilkd 182(4), 331 (SF6)
Conjunctivitis
Ocular allergy
Ocular stinging
(1997): Lund K+, Occup Environ Med 54(1), 32 (HF)
Other
Abdominal pain
(1994): Das TK+, J Clin Gastroenterol 18(3), 194
Adverse effects (sic)
(2003): Marinho VC+, JDentEduc67(4), 448
(2002): Ringe JD+, Rheumatol Int 22(1), 27 (mild)
(1997): Gotjamanos T+, Aust Dent J 42(1), 52
(1993): Spittle B, Fluoride 26(4), 267
(1992): Garcia-Sanchez MJ+, Rev Esp Anestesiol Reanim
39(5), 285 (isoflurane)
(1992): Muller P+, Z Gastroenterol 30(4), 252 (NaF) (4 cases)
(1987): Hasling C+, Miner Electrolyte Metab 13(2), 96 (51%)
(NaF + Ca + vitamin D)
(1985): Dubovsky J+, Ala Med 54(12), 47
Death
(1998): Klasner AE+, Ann Emerg Med 31(4), 525
(1998): Mullins ME+, Ann Emerg Med 31(4), 524 (HF)
(1996): Tohyama E, JEpidemiol6(4), 184
(1994): Arnow PM+, AnnInternMed121(5), 339 (hemodialysis)
(1987): Mullett T+, J Burn Care Rehabil 8(3), 216 (HF)
(1985): Mayer TG+, Ann Emerg Med 14(2), 149 (HF)
(1980): Tepperman PB, J Occup Med 22(10), 691 (HF)
Hypersensitivity
(1996): Lopez-Serrano MC+, J Investig Allergol Clin Immunol
6(5), 324 (F-containing corticosteroids)
(1996): Soyseth V+, Allergy 51(10), 719 (environmental
exposure)
(1993): Isaksson M+, Scand J Dent Res 101(1), 49 (Duraphat)
(1993): Spittle B, Fluoride 26(4), 267
(1990): Kaminsky LS+, Crit Rev Oral Biol Med 1(4), 261
(1988): Razak IA+, Ann Dent 47(2), 37 (SF)
Toxicity (sic)
(2001): Chang YC+, Oral Surg Oral Med Oral Pathol Oral Radiol
Endod 91(2), 230
(2001): Gupta SK+, Indian Pediatr 38(2), 139
(2001): Kleinsasser NH+, Laryngorhinootologie 80(4), 187
(2001): Lubben B+, Laryngorhinootologie 80(4), 214
(2000): Masters RD+, Neurotoxicology 21(6), 1091
(1999): Sjostrom S+, J Clin Periodontol 26(4), 257 (SF gel)
(1997): Gotjamanos T+, Aust Dent J 42(1), 52
(1997): Lochhead KM+, Am J Pathol 150(6), 2209 (F anesthetics)
(1997): Shulman JD+, J Public Health Dent 57(3), 150
(1996): Cittanova ML+, Anesthesiology 84(2), 428 (F anesthetics)
(1996): Klasaer AE+, Ann Emerg Med 28(6), 713 (HF)
(1994): Das TK+, J Clin Gastroenterol 18(3), 194
(1993): Bordelon BM+, JTrauma34(3), 437 (HF)
(1992): Whitford GM, J Dent Res 71(5), 1249
(1990): Spak CJ+, J Dent Res 69(2), 426
(1988): Caravati EM, Am J Emerg Med 6(2), 143 (HF)
(1988): Greco RJ+, JTrauma28(11), 1593 (HF) (3 cases)
(1987): Lantz O+, Am J Kidney Dis 10(2), 136 (Vichy water)
(1987): Whitford GM, J Dent Res 66(5), 1056 (5.0 mg F/kg)
(1987): Whitford GM+, J Dent Res 66(5), 1072 (APF gel)
(1987): Zaborra G+, Stomatol Mediterr 7(3), 387
(1985): Bayless JM+, J Am Dent Assoc 110(2), 209
(1984): Mazze RI, Can Anaesth Soc J 31(3 Pt 2), S16
(methoxyflurane)
FLUOROURACIL
Trade names: Carac (Dermik); Efudex (Valeant); Efudix; Efurix;
Fluoroplex (Allergan)
Category: Antimetabolite; Antineoplastic
Half-life: 8–20 minutes
Clinically important, potentially hazardous interactions
with: aldesleukin, bromelain, cimetidine, granulocyte colonystimulating
factor (GCSF)), metronidazole
Reactions
Skin
Acral erythema
(2007): Adachi A+, Dermatology 214(1), 85
(1995): Esteve E+, Ann Med Interne Paris (French) 146, 192
(1992): Doll DC+, Semin Oncol 19(5), 580
(1989): Vukelja SJ+, AnnInternMed111, 688
Actinic keratoses
(1999): Nabai H+, Cutis 64, 43
(1987): Johnson TM+, JAmAcadDermatol17(2 Pt 1), 192
Angioedema
Bullous dermatitis
Dermatitis (>10%)
(1999): Sanchez-Perez J+, Contact Dermatitis 41, 106
(1997): Anderson LL+, JAmAcadDermatol36, 478
(1996): Nadal C+, Contact Dermatitis 35, 124 (systemic)
Diaphoresis
(1994): Anand AJ, Ann Pharmacother 28(3), 374
Eczema